|
|
|
|
|
|
Products |
| |
|
| |
During the past 15 years InSight has developed a wide portfolio of Biosimilars manufacturing technologies and products.
The "first generation" of off-patent products developed and commercialized by InSight included:
- Interferon alpha (2a) - Interferon alpha (2b) - Interferon beta-1a - Interferon beta-1b - EPO - G-CSF - GM-CSF - HGH
Main Focus:
Currently, our focus is on the "second generation" of Biosimilars - monoclonal antibodies.
For more information about our current portfolio please visit our "Biogenrics Products" section. biogenerics products
|
| |
|
| |
|
|
|